Can BACE2 Protect Against Amyloidosis?
The protease suppresses Aβ in Down’s syndrome organoids.
NEWS
CryoEM of CBD Tau Suggests Another Unique Protofibril
Post-translational modifications differ from those in AD tau fibrils, and may dictate tau strains.
New Myelin Makes Memories, but Supply Wanes with Age
The creation of long-term memories requires a continual supply of myelin provided by newly formed oligodendrocytes. Alas, the generation of fresh oligodendrocytes diminishes with age, along with memory.
Paper Alert: Phase 3 Trial Data Published on Sleep Aid Suvorexant
FDA approves adding safety and efficacy data from an Alzheimer’s trial to the drug’s label.
Topline Result for First DIAN-TU Clinical Trial: Negative on Primary
DIAN, Roche, Lilly disclose that neither gantenerumab nor solanezumab slowed cognitive decline in the first-pass comparison of drug and placebo groups. Analyses are ongoing; dose may have been too low.
Multimodal Imaging of Neurodegenerative Diseases Links Pathology and Cellular Dysfunction
Synapse loss and mitochondrial stress, as seen by separate PET tracers, go hand-in-hand in Alzheimer’s, Parkinson’s, and frontotemporal dementia.
PET Tracer Detects Synapse Loss Across Alzheimer’s Brain
New research presented at the HAI conference also finds links between UCB-J uptake and plaques, tangles, and cognitive decline.
Toxic α-Synuclein: Egged on by ApoE4, Thwarted by ApoE2?
Quite independently of what it does to Aβ or tau, ApoE4 stokes α-synuclein pathology in mouse models. People with Lewy body dementia who carry ApoE4 had more phosphorylated synuclein in their brains, and their cognition declined faster.
Virtual Exhibit Hall
Alzforum encourages users to visit the Virtual Exhibit Hall, where companies showcase their newest initiatives, products, and services. We welcome F. Hoffmann-La Roche, joining our other exhibitors — Biogen, BioLegend, Dash Genomics, Inc., Abcam, BrainXell, and the Jackson Laboratory.
SPOTLIGHT
Topline Result for DIAN-TU Clinical Trial: Negative on Primary
Monday, February 10, was a painful day for DIAN families around the world. DIAN investigators, Roche, and Lilly disclosed that neither gantenerumab nor solanezumab had slowed cognitive decline in the first-pass comparison of drug and placebo groups. The comparison grouped asymptomatic and symptomatic participants together. Dosing for both antibodies was increased midway through this five- to seven-year trial. Results on secondary outcomes and on biomarkers, as well as analyses of more individualized trajectories, are still to come; additional DIAN trials remain on track. Participating families are grappling with the setback, and vowing to keep on fighting dominantly inherited Alzheimer’s disease.
Join The Conversation
Professional Resources
New in last 7 days
-
Grants
- New Items: 8
- Total Items: 498
-
Jobs
- New Items: 4
- Total Items: 98
-
Conference Calendar
- New Items: 1
- Total Items: 66
- Member Directory
Latest Comments